Anti-HER2 antibody toxin conjugate - TopoTargetAlternative Names: Zemab
Latest Information Update: 16 Jul 2010
At a glance
- Originator Novartis
- Developer TopoTarget
- Class Antineoplastics; Immunotoxins
- Mechanism of Action ERBB 2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2010 No development reported - Phase-I for Cancer in Denmark (Intratumoural)
- 15 May 2007 Phase-I clinical trials in Cancer in Denmark (Intratumoural)